Skip to main content
SpringerLink
Log in

Anemia and Erythropoeitic Growth Factors in Multiple Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 523 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyle, R.A., et al., Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc, 2003. 78(1): p.21–33.

    Article  PubMed  Google Scholar 

  2. Birgegard, G., P. Gascon, and H. Ludwig, Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol, 2006. 77(5): p.378–86.

    Article  PubMed  Google Scholar 

  3. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 2003. 121(5): p.749–57.

    Google Scholar 

  4. Caro, J.J., et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 2001. 91(12): p.2214–21.

    Article  PubMed  CAS  Google Scholar 

  5. Rosinol, L., et al., Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol, 2003. 123(4): p.631–6.

    Article  PubMed  CAS  Google Scholar 

  6. Rajkumar, S.V., MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program, 2005: p.340–5.

    Google Scholar 

  7. Hirashima, K. and F. Takaku, Experimental studies on erythropoietin. II. The rela tionship between juxtaglomerular cells and erythropoietin. Blood, 1962. 20: p.1–8.

    PubMed  CAS  Google Scholar 

  8. Astor, B.C., et al., Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med, 2002. 162(12): p.1401–8.

    Article  PubMed  Google Scholar 

  9. Blade, J., et al., Renal failure in multiple myeloma: presenting features and predic tors of outcome in 94 patients from a single institution. Arch Intern Med, 1998. 158(17): p.1889–93.

    Article  PubMed  CAS  Google Scholar 

  10. Pasqualetti, P., A. Collacciani, and R. Casale, Circadian rhythm of serum erythro-poietin in multiple myeloma. Am J Hematol, 1996. 53(1): p.40–2.

    Article  PubMed  CAS  Google Scholar 

  11. Baer, A.N., et al., Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol, 1987. 66(4): p.559–64.

    Article  PubMed  CAS  Google Scholar 

  12. Miller, C.B., et al., Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med, 1990. 322(24): p.1689–92.

    Article  PubMed  CAS  Google Scholar 

  13. Beguin, Y., et al., Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol, 1992. 82(4): p.648–53.

    Article  PubMed  CAS  Google Scholar 

  14. Majumdar, G., et al., Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure. Leuk Lymphoma, 1993. 9(1–2): p.173–6.

    Article  PubMed  CAS  Google Scholar 

  15. Bondurant, M.C. and M.J. Koury, Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol, 1986. 6(7): p.2731–3.

    PubMed  CAS  Google Scholar 

  16. Jelkmann,W., Proinflammatory cytokines lowering erythropoietin production J Interferon Cytokine Res, 1998. 18(8): p.555–9.

    Article  PubMed  CAS  Google Scholar 

  17. Pisa, P., et al., Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients. Anticancer Res, 1990. 10(3): p.817–20.

    PubMed  CAS  Google Scholar 

  18. Barany, P., J.C. Divino Filho, and J. Bergstrom, High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis, 1997. 29(4): p.565–8.

    Article  PubMed  CAS  Google Scholar 

  19. Aoki, I., et al., Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma Br J Haematol, 1992. 81(4): p.463–9.

    Article  PubMed  CAS  Google Scholar 

  20. Taniguchi, S., et al., Interferon gamma downregulates stem cell factor and erythro-poietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood, 1997. 90(6): p.2244–52.

    PubMed  CAS  Google Scholar 

  21. Maciejewski, J.P., et al., Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest, 1995. 96(2): p.1085–92.

    Article  PubMed  CAS  Google Scholar 

  22. Sato, T., et al., Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. Blood, 1995. 86(9): p.3373–80.

    PubMed  CAS  Google Scholar 

  23. Selleri, C.,et al., Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol, 1995. 165(3): p.538–46.

    Article  PubMed  CAS  Google Scholar 

  24. Pigeon, C., et al., A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload J Biol Chem, 2001. 276(11): p.7811–9.

    Article  PubMed  CAS  Google Scholar 

  25. Nemeth, E., et al., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004. 306(5704): p.2090–3.

    Article  PubMed  CAS  Google Scholar 

  26. Truksa, J., et al., Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA, 2006. 103(27): p.10289–93.

    Article  PubMed  CAS  Google Scholar 

  27. Nicolas, G., et al., The gene encoding the iron regulatory peptide hepcidin is regu lated by anemia, hypoxia, and inflammation. J Clin Invest, 2002.110(7): p.1037–44.

    PubMed  CAS  Google Scholar 

  28. Nemeth, E., et al., IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest, 2004. 113(9): p.1271–6.

    PubMed  CAS  Google Scholar 

  29. Theurl, I., et al., Dysregulated monocyte iron homeostasis and erythropoietin forma tion in patients with anemia of chronic disease. Blood, 2006. 107(10): p.4142–8.

    Article  PubMed  CAS  Google Scholar 

  30. Cline, M.J. and N.I. Berlin, Studies of the anemia of multiple myeloma. Am J Med, 1962. 33: p.510–25.

    Article  PubMed  CAS  Google Scholar 

  31. Cartwright, G.E., The anemia of chronic disorders. Semin Hematol, 1966. 3(4): p.351–75.

    PubMed  CAS  Google Scholar 

  32. Larsson, S.O., Myeloma and pernicious anaemia. Acta Med Scand, 1962. 172: p.195–205.

    Article  PubMed  CAS  Google Scholar 

  33. Hsing, A.W., et al., Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer, 1993. 71 (3): p.745–50.

    Article  PubMed  CAS  Google Scholar 

  34. Baz, R., et al., Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer, 2004. 101(4): p.790–5.

    Article  PubMed  Google Scholar 

  35. Fossa, A., et al., Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma. Exp Hematol, 1999. 27(11): p.1621–6.

    Article  PubMed  CAS  Google Scholar 

  36. Silvestris, F., et al., Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood, 2001. 97(5): p.1155–64.

    Article  PubMed  CAS  Google Scholar 

  37. Silvestris, F., et al., Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood, 2002. 99(4): p.1305–13.

    Article  PubMed  CAS  Google Scholar 

  38. Richardson, P.G., et al., A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003. 348(26): p.2609–17.

    Article  PubMed  CAS  Google Scholar 

  39. Rajkumar, S.V., et al., Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005. 106(13): p.4050–3.

    Article  PubMed  CAS  Google Scholar 

  40. Cella, D., The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue Semin Hematol, 1997. 34(3 Suppl 2): p.13–9.

    PubMed  CAS  Google Scholar 

  41. Littlewood, T.J., et al., Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 2001. 19(11): p.2865–74.

    PubMed  CAS  Google Scholar 

  42. Osterborg, A., et al., Randomized, double-blind, placebo-controlled trial of recom binant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol, 2002. 20(10): p.2486–94.

    Article  PubMed  CAS  Google Scholar 

  43. Hedenus, M., et al., Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol, 2003. 122(3): p.394–403.

    Article  PubMed  CAS  Google Scholar 

  44. Glaspy, J., et al., Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol, 1997. 15(3): p.1218–34.

    PubMed  CAS  Google Scholar 

  45. Demetri, G.D., et al., Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol, 1998. 16(10): p.3412–25.

    PubMed  CAS  Google Scholar 

  46. Gabrilove, J.L., et al., Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol, 2001. 19(11): p.2875–82.

    PubMed  CAS  Google Scholar 

  47. Boccia, R., et al., The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist, 2007. 12(5): p.584–93.

    Article  PubMed  CAS  Google Scholar 

  48. Straus, D.J., et al., Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer, 2006. 107(8): p.1909–17.

    Article  PubMed  CAS  Google Scholar 

  49. Crawford, J., et al., Relationship between changes in hemoglobin level and qual ity of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 2002. 95(4): p.888–95.

    Article  PubMed  CAS  Google Scholar 

  50. Wisloff, F., et al., Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol, 2005. 75(4): p.293–8.

    Article  PubMed  Google Scholar 

  51. Bergsagel, D.E., et al. Treatment of anemia associated with multiple myeloma N Engl J Med, 1991. 324(1): p.59–60.

    Article  PubMed  CAS  Google Scholar 

  52. Hebert, P.C., et al., A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med, 1999. 340(6): p.409–17.

    Article  PubMed  CAS  Google Scholar 

  53. Lacroix, J., et al., Transfusion strategies for patients in pediatric intensive care units. N Engl J Med, 2007. 356(16): p.1609–19.

    Article  PubMed  CAS  Google Scholar 

  54. Khuri, F., Weighing the hazards of erythropoiesis stimulation in patients with can cer. N Engl J Med, 2007. 356(24): p.2445–8.

    Article  PubMed  CAS  Google Scholar 

  55. Elliott, S., et al., Control of rHuEPO biological activity: the role of carbohydrate Exp Hematol, 2004. 32(12): p.1146–55.

    Article  PubMed  CAS  Google Scholar 

  56. Bohlius, J., et al., Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev, 2006. 3: p.CD003407.

    PubMed  CAS  Google Scholar 

  57. Mittelman, M., et al., Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA, 2001. 98(9): p.5181–6.

    Article  PubMed  CAS  Google Scholar 

  58. Prutchi-Sagiv, S., et al., Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol, 2006. 135(5): p.660–72.

    Article  PubMed  CAS  Google Scholar 

  59. Silvestris, F., et al., Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol, 1995. 70(6): p.313–8.

    Article  PubMed  CAS  Google Scholar 

  60. Barrios, M. and C. Alliot, IgA multiple myeloma responding to erythropoietin monotherapy. Am J Hematol, 2005. 80 (2): p.165–6.

    Article  PubMed  Google Scholar 

  61. Mittelman, M., et al., Erythropoietin has an anti-myeloma effect — a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol, 2004. 72(3): p.155–65.

    Article  PubMed  CAS  Google Scholar 

  62. Baz, R., et al., Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol, 2007. 117(3): p.162–7.

    Article  PubMed  CAS  Google Scholar 

  63. Bohlius, J., et al., Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, 2006. 98(10): p.708–14.

    Article  PubMed  CAS  Google Scholar 

  64. Lee, M.S., J.S. Lee, and J.Y. Lee, Prevention of erythropoietin-associated hyperten sion. Hypertension, 2007.

    Google Scholar 

  65. Gleason, K., et al., Recombinant erythropoietin (Epo)darbepoetin (Darb) associated venous thromboembolism (VTE) in the oncology setting: findings from the Research on Adverse Drug Events and Reports (RADAR) project. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I., 2007. 25(18S): p.2552.

    Google Scholar 

  66. Steurer, M., et al., Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol, 2003. 121(1): p.101–3.

    Article  PubMed  CAS  Google Scholar 

  67. Knight, R., R.J. DeLap, and J.B. Zeldis, Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med, 2006. 354(19): p.2079–80.

    Article  PubMed  CAS  Google Scholar 

  68. Galli, M., et al., Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica, 2004. 89(9): p.1141–2.

    PubMed  CAS  Google Scholar 

  69. Baz, R., et al., An analysis of erythropoietin (Epo) and venous thromboembolic events (VTE) in multiple myeloma (MM) patients (pts) treated with anthracycline-based chemotherapy and the immunomodulator agent thalidomide. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I., 2007. 25(18S): p.8107.

    Google Scholar 

  70. Singh, A.K., et al. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med, 2006. 355(20): p.2085–98.

    Article  PubMed  CAS  Google Scholar 

  71. Seidenfeld, J., et al., Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative effectiveness review no. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practive Center under Contract No. 290-02-0026). Agency for Healthcare Research and Quality, 2006 (available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm).

  72. Henke, M., et al., Erythropoietin to treat head and neck cancer patients with anae mia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 2003. 362(9392): p.1255–60.

    Article  PubMed  CAS  Google Scholar 

  73. Leyland-Jones, B., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol, 2005. 23(25): p.5960–72.

    Article  PubMed  CAS  Google Scholar 

  74. Olujohungbe, A.,S. Handa, and J. Holmes, Does erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J, 1997. 73(857): p.163–4.

    Article  PubMed  CAS  Google Scholar 

  75. Okuno, Y., et al., Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth. Leukemia, 1991. 5(7): p.585–91.

    PubMed  CAS  Google Scholar 

  76. Glaspy, J., Results from a Phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa (DA) for th treatment of anemia in patients not receiv ing chemotherapy or radiotherapy. Presented April 16, 2007 at the American Association for Cancer Research Meeting, 2007.

    Google Scholar 

  77. Longmore, G.D., Do cancer cells express functional erythropoietin receptors? N Engl J Med, 2007. 356(24): p.2447.

    Article  PubMed  CAS  Google Scholar 

  78. Kaufman, J.S., et al., Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med, 1998. 339(9): p.578–83.

    Article  PubMed  CAS  Google Scholar 

  79. Justice, G., et al., A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol, 2005. 16(7): p.1192–8.

    Article  PubMed  CAS  Google Scholar 

  80. Granetto, C., et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep, 2003. 10(5): p.1289–96.

    PubMed  CAS  Google Scholar 

  81. Hesketh, P.J., et al., A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer, 2004. 100(4): p.859–68.

    Article  PubMed  CAS  Google Scholar 

  82. Cheung, W., N. Minton, and K. Gunawardena, Pharmacokinetics and pharmacody-namics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol, 2001. 57(5): p.411–8.

    Article  PubMed  CAS  Google Scholar 

  83. Canon, J.L., et al., Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, 2006. 98(4): p.273–84.

    Article  PubMed  CAS  Google Scholar 

  84. Rivera, S., et al., Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood, 2005. 105(4): p.1797–802.

    Article  PubMed  CAS  Google Scholar 

  85. Auerbach, M., et al., Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol, 2004. 22(7): p.1301–7.

    Article  PubMed  CAS  Google Scholar 

  86. Henry, D.H., et al., Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist, 2007. 12(2): p.231–42.

    Article  PubMed  CAS  Google Scholar 

  87. Hedenus, M., et al., Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoprolifer ative malignancies: a randomized multicenter study. Leukemia, 2007. 21(4): p.627–32.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Boston, MA, USA

    Noopur Raje

Authors
  1. Mark J Sloan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noopur Raje
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sloan, M.J., Raje, N. (2008). Anemia and Erythropoeitic Growth Factors in Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_28

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation